Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall 2023 and Spring 2024 in France. The number of symptomatic SAR...

Full description

Saved in:
Bibliographic Details
Main Authors: Amy Lee, Benjamin Davido, Ekkehard Beck, Clarisse Demont, Keya Joshi, Michele Kohli, Michael Maschio, Mathieu Uhart, Nadia El Mouaddin
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
COVID-19 vaccine
economic modeling
decision analysis
COVID-19 hospitalization
vaccine effectiveness
France
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2423474
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items